Valuation: Genmab A/S

Market Cap 138B 20.81B 18.48B 17.28B 15.75B 29.65B 2,003B 30.06B 209B 80.93B 1,020B 78.11B 76.42B 3,277B P/E 2026 *
28.8x
P/E 2027 * 20.5x
Enterprise Value 157B 23.7B 21.05B 19.69B 17.94B 33.77B 2,282B 34.24B 238B 92.19B 1,162B 88.98B 87.05B 3,733B EV / Sales 2026 *
5.42x
EV / Sales 2027 * 4.42x
Free-Float
94.3%
Yield 2026 *
-
Yield 2027 * -
1 day-1.28%
1 week+1.98%
Current month-1.28%
1 month+7.73%
3 months+28.50%
6 months+31.53%
Current year+14.11%
1 week 2,270
Extreme 2270
2,369
1 month 2,066
Extreme 2066
2,369
Current year 1,512
Extreme 1512
2,369
1 year 1,512
Extreme 1512
2,369
3 years 1,157
Extreme 1157
2,532
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 2010-05-31
Director of Finance/CFO 48 2020-02-29
Chief Tech/Sci/R&D Officer - 2024-08-15
Director TitleAgeSince
Director/Board Member 75 2003-10-31
Director/Board Member 58 2014-12-31
Director/Board Member 75 2014-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
12/1/25 Exercice

Director

189 0.0003%
12/1/25 Exercice

Director

189 0.0003%
12/1/25 Exercice

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%+1.98%+16.44%-7.78% 21.27B
+4.16%+3.04%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+82.72% 60.14B
-2.54%-1.65%+4.86%+31.72% 48.15B
-3.02%-5.20%+27.94%+32.51% 44.25B
+0.31%+3.02%+348.95%+643.82% 43.99B
-1.96%-0.33%+7.04%+99.46% 41.61B
+3.32%+3.49%+10.10%+51.23% 29.97B
-3.57%+2.17%+28.68%+21.82% 29.31B
-4.86%-10.66%-26.27%+330.06% 24.93B
Average -0.99%+0.16%+49.44%+137.97% 41.81B
Weighted average by Cap. -0.48%+0.22%+55.66%+137.90%

Financials

2026 *2027 *
Net sales 29.05B 4.37B 3.88B 3.63B 3.31B 6.23B 421B 6.32B 43.95B 17.01B 214B 16.42B 16.06B 689B 33.74B 5.08B 4.51B 4.22B 3.84B 7.24B 489B 7.34B 51.04B 19.76B 249B 19.07B 18.66B 800B
Net income 4.98B 750M 666M 623M 567M 1.07B 72.18B 1.08B 7.53B 2.92B 36.76B 2.81B 2.75B 118B 7.17B 1.08B 959M 897M 817M 1.54B 104B 1.56B 10.85B 4.2B 52.95B 4.05B 3.97B 170B
Net Debt 19.23B 2.9B 2.57B 2.4B 2.19B 4.13B 279B 4.18B 29.09B 11.26B 142B 10.87B 10.63B 456B 11.08B 1.67B 1.48B 1.39B 1.26B 2.38B 161B 2.41B 16.76B 6.49B 81.8B 6.26B 6.13B 263B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
26-10-01 DKK 2,313.00 -1.28% 148,995
26-09-30 DKK 2,343.00 +1.12% 185,142
26-09-29 DKK 2,317.00 +0.65% 142,718
26-09-28 DKK 2,302.00 +1.10% 122,997
26-09-25 DKK 2,277.00 +0.40% 99,355
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
2,313.00DKK
Average target price
2,453.79DKK
Spread / Average Target
+6.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock